Carticept Medical
Enhancing patient outcomes with advanced treatments for osteoarthritis and cartilage damage through innovative implants and leading ultrasound solutions.
Enhancing patient outcomes with advanced treatments for osteoarthritis and cartilage damage through innovative implants and leading ultrasound solutions.
Carticept Medical, established in 2005, focuses on enhancing patient outcomes by offering advanced treatments for osteoarthritis and cartilage damage through innovative implants and leading ultrasound solutions. The company’s commitment lies in developing therapies that improve the quality of life for patients with osteoarthritis or cartilage damage. Currently, Carticept Medical provides a cartilage implant product and distributes Sonosite ultrasound products. In its latest funding round, the company secured a noteworthy $10.00M Series C investment on 18 January 2012, with participation from prominent investors including New Enterprise Associates, Domain Associates, and Sonosite. Carticept Medical primarily operates within the Health Care, Health and Wellness, and Medical Devices industries.
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Series C | $10.00M | 3 |
|
18 Jan 2012 |
| Series B | $20.00M | 3 |
|
10 Mar 2010 |
| Series A | Unknown | 2 |
|
23 Feb 2007 |
| Series A | Unknown | - | 19 Oct 2005 |
No recent news or press coverage available for Carticept Medical.
We care about your data, and we'd love to use cookies make your experience better.
